Liquidia Corporation

We are deeply passionate and committed to the discovery, engineering, and development required to bring novel therapies to patients who need them most, and to the healthcare providers who care for them. Our current drive is toward improving the treatment of pulmonary arterial hypertension (PAH).

We will continue to combine our proprietary, innovative PRINT Technology with new and established medications, offering the potential for both better precision and improved clinical outcomes.

News Releases

APR 13 2021

Liquidia Corporation Announces $21.7 Million Private Placement

RESEARCH TRIANGLE PARK, N.C. , April 13, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it has entered into a common stock purchase agreement with certain institutional, accredited investors for the private placement of 8,626,037 shares of common stock at a
APR 07 2021

Liquidia Corporation To Present At The 20th Annual Needham Virtual Healthcare Conference

RESEARCH TRIANGLE PARK, N.C. , April 07, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Damian deGoa, Chief Executive Officer of Liquidia , will provide an overview and update on the company's business during a fireside chat session at the 20th Annual Needham

btn News